Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline
With funding round by M Ventures, Safar Partners and Horizons Ventures Concerto progresses vision to reinvent humanity’s relationship with microbes
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
• Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises
• Nucleome’s pioneering platform seeks to identify direct genetic linkages to disease-associated genes for drug discovery
• Funds will advance Nucleome’s autoimmune disease programmes and fuel expansion of its dark genome atlas
Tignis, a technology innovator in AI process control for semiconductor manufacturing, today announced it has received Series A funding from M Ventures, the strategic corporate venture arm of Merck, KGaA, Darmstadt, Germany—a leading science and technology company. This investment brings Tignis’ total Series A funding received in 2022 to $10 million. Tignis was introduced to M Ventures through the SEMI Startups for Semiconductor Sustainability program.
Electroninks, Inc., today announced the production-scale availability of its full suite of proprietary metal organic decomposition (MOD) conductive metal ink solutions. In addition to bringing standalone ink products to market, Electroninks is also bringing total solutions to the customer with its line of ink products, including its own small (desktop) prototype additive manufacturing solution for rapid on-demand printed circuit board (PCB) printing and repair, called CircuitJet.
SynSense, announced that it will advance the integration of neuromorphic chips and smart cockpits and explore related fields with BMW. This marks the entry point for the application of SynSense’s brain-like technology into smart cockpits
iOnctura has preclinical data that shows its autotaxin inhibitor IOA-289 both inhibits pancreatic cells directly and inhibits the cancerpromoting activity of secreted factors from Cancer-Associated Fibroblasts (CAFS)
iOnctura SA will present preclinical data on its next-generation autotaxin inhibitor, IOA-289, at the annual meeting of the American Association for Cancer Research (AACR) taking place on April 8-13, 2022 in New Orleans, Louisiana.